Tokyo, Sept. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058865) titled 'Evaluation of Bedside Quantitative Sensory Testing for Predicting the Prognosis of PRF in Acute Herpes Zoster Patients' on Sept. 1.

Study Type: Observational

Primary Sponsor: Institute - Sendai Pain Clinic

Condition: Condition - Herpes Zoster Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Zoster associated pain is characterized by intense neuropathic pain from the early stages of onset. Inadequate treatment during the acute to subacute phase may lead to the development of postherpetic neuralgia, a form of chronic intractable pain that significantly impairs patients' quality of life. Pulsed radiofrequency treatment, which modulates the function of the dorsal root ganglion without causing neural destruction, has been utilized as a minimally invasive and effective option for both ZAP and PHN. However, PRF is not uniformly effective. Some studies have reported that a proportion of patients treated with DRG targeted PRF still develop PHN, and to date, there are no established predictors for identifying patients who are most likely to benefit from this intervention. This research seeks to clarify the potential role of QST as a predictive tool for PRF responsiveness in the early stages of herpes zoster-associated neuropathic pain. Basic objectives2 - Others

Eligibility: Age-lower limit - 20 years-old = Gender - Male and Female Key inclusion criteria - Eligible participants were patients aged 20 years or older who presented to the Sendai Pain Clinic for an initial consultation with acute to subacute zoster-associated pain (ZAP) involving the thoracic region (Th2 to Th12) within three months of rash onset, and who provided informed consent to undergo pulsed radiofrequency (PRF) treatment. Key exclusion criteria - (1) patients with severe psychiatric disorders, including cognitive impairment (2) patients with unidentified chronic pain conditions unrelated to herpes zoster (3) patients with severe cardiovascular, respiratory, renal, or hepatic diseases (4) patients with poorly controlled diabetes mellitus (defined as HbA1c > 8.0%) (5) patients with known allergies to local anesthetics or corticosteroids (6) patients who had received neurolytic blocks related to herpes zoster within the past month (7) patients with severe dermatological conditions or active infections at the QST measurement sites. Target Size - 50

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 07 Month 03 Day Date of IRB - 2025 Year 07 Month 03 Day Anticipated trial start date - 2025 Year 09 Month 01 Day Last follow-up date - 2027 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065847

Disclaimer: Curated by HT Syndication.